Ignite Creation Date:
2024-05-06 @ 2:02 PM
Last Modification Date:
2024-10-26 @ 1:24 PM
Study NCT ID:
NCT04197986
Status:
TERMINATED
Last Update Posted:
2024-03-13
First Post:
2019-12-02
Brief Title:
Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations
Sponsor:
QED Therapeutics Inc
Organization:
QED Therapeutics Inc
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-03-11
Start Date Type:
ACTUAL
Primary Completion Date:
2023-02-28
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-02-28
Completion Date Type:
ACTUAL
First Submit Date:
2019-12-02
First Submit QC Date:
December 12 2019
Study First Post Date:
2019-12-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2024-03-13
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-02-16
Last Update Post Date:
2024-03-13
Last Update Post Date Type:
ACTUAL